Myriad Genetics, Inc. Share Price & Technical Analysis
MYGN · $3.82 (-2.30%)
Healthcare / Diagnostics & Research
$3.82
-2.30%
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovari…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-19% return in May, -8% avg return in past 3 year May month.
-50% return in 2026, -4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -10% | -16% | -12% | 7% | -19% | – | – | – | – | – | – | – | -50% |
| 25 | -8% | -14% | -18% | -17% | -43% | 26% | -28% | 68% | 13% | 10% | -6% | -17% | -35% |
| 24 | 13% | -3% | 1% | -8% | 16% | 11% | 15% | 1% | -3% | -20% | -18% | -15% | -10% |
| 23 | 33% | -4% | 18% | -7% | 4% | 5% | -3% | -20% | -12% | -2% | 22% | -1% | 34% |
| 22 | -5% | -7% | 3% | -19% | -6% | -6% | 46% | -15% | -14% | 8% | 5% | -29% | -39% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$387.71M
P/E ratio
—
52W high
$8.59
52W low
$3.53
Volume
10,34,572
Beta
1.64
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Myriad Genetics, Inc. share price today?
- Myriad Genetics, Inc. (MYGN) last traded around $3.82 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MYGN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MYGN. Download the app for real-time alerts.
- How can I analyze Myriad Genetics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.